

Ref: CTO 2015 064 [1]

Horse: Third Country Residency - Columbia

CTO direction to biosecurity inspectors for the clearance the horse "TIRO AL BLANCO"

Pursuant to section 27(1)(d)(iii) of the Biosecurity Act 1993 I, Marnie Thomas, Manager Animal Imports, Ministry for Primary Industries (under delegated authority), give the following directions for the horse "TIRO AL BLANCO", identified on permit number 2015058069 to be given clearance in accordance with the following measures, different from those on the veterinary certificate for horses from the United States negotiated under the Import Health Standard for Horses *HORANIIC.GEN* (22 May 2014):

Dourine, glanders and Venezuelan equine encephalomyelitis (VEE): residency in the United States for a minimum period of 6 (six) months.

The horse "TIRO AL BLANCO" was imported into the United States from Columbia and will have been resident in the United States for less than the required 6 months at the time of export to New Zealand. The IHS measures follow the World Organisation for Animal Health (OIE) *Terrestrial Animal Health Code* (the *Code*) recommendations including the option of testing for these three diseases when the animal doesn't meet the residency requirements. It was agreed with the United States Department of Agriculture (USDA) that the horse will be tested for these diseases during pre-export isolation (PEI).

The horse "TIRO AL BLANCO" must be accompanied by the supplementary attestation agreed on with the USDA and the laboratory reports for dourine, glanders and VEE.

For dourine and glanders, the *Code* also recommends residency on premises free from dourine/glanders for 6 months. The horse "TIRO AL BLANCO" will have met this premises freedom requirement when leaving post-arrival quarantine (PAQ). The horse must show no clinical signs of dourine, glanders or VEE during PAQ in order to receive biosecurity clearance.

This CTO direction is valid only for the horse "TIRO AL BLANCO" identified on permit number 2015058069.

The reason for directing clearance is that the biosecurity risks associated with this CTO direction have been assessed and are managed effectively.